Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply.

Buurman DJ, Vande Casteele N, Sturkenboom MG, Kleibeuker JH, Vermeire S, van der Kleij D, Rispens T, Gils A, Dijkstra G.

Aliment Pharmacol Ther. 2013 Jan;37(2):282. doi: 10.1111/apt.12128. No abstract available.

2.

Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays.

Parussini E.

Aliment Pharmacol Ther. 2013 Jan;37(2):281. doi: 10.1111/apt.12130. No abstract available.

3.

Commentary: detection of infliximab levels and anti-infliximab antibodies.

Seow CH, Panaccione R.

Aliment Pharmacol Ther. 2013 Jan;37(1):153-4. doi: 10.1111/apt.12107. No abstract available.

4.

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G.

Aliment Pharmacol Ther. 2012 Oct;36(8):765-71. doi: 10.1111/apt.12030. Epub 2012 Aug 28.

5.

Letter: measurement of anti-TNF-α levels and antibodies against the drug.

Chaparro M, Gisbert JP.

Aliment Pharmacol Ther. 2013 Jan;37(1):163-4. doi: 10.1111/apt.12106. No abstract available.

6.

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.

Imaeda H, Andoh A, Fujiyama Y.

J Gastroenterol. 2012 Feb;47(2):136-43. doi: 10.1007/s00535-011-0474-y. Epub 2011 Sep 28.

PMID:
21953314
7.

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.

Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y.

Gut. 2011 Jan;60(1):41-8. doi: 10.1136/gut.2009.201533. Epub 2010 Jun 2.

PMID:
20519742
8.

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.

Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.

Scand J Gastroenterol. 2011 Mar;46(3):310-8. doi: 10.3109/00365521.2010.536254. Epub 2010 Nov 18.

PMID:
21087119
9.

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.

Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, Lockton S, Ling N, Singh S.

J Immunol Methods. 2012 Aug 31;382(1-2):177-88. doi: 10.1016/j.jim.2012.06.002. Epub 2012 Jun 9.

10.

Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab.

Kosmač M, Avčin T, Toplak N, Simonini G, Cimaz R, Curin Šerbec V.

Pediatr Res. 2011 Mar;69(3):243-8. doi: 10.1203/PDR.0b013e318208451d.

PMID:
21131896
11.

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.

Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A.

Rheumatology (Oxford). 2011 Aug;50(8):1445-52. doi: 10.1093/rheumatology/ker124. Epub 2011 Mar 22.

PMID:
21427177
12.

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.

Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K.

Ann Rheum Dis. 2009 Nov;68(11):1739-45. doi: 10.1136/ard.2008.092833. Epub 2008 Nov 19.

PMID:
19019895
13.
14.

Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.

Stubenrauch K, Wessels U, Lenz H.

J Pharm Biomed Anal. 2009 May 1;49(4):1003-8. doi: 10.1016/j.jpba.2009.01.030. Epub 2009 Feb 5.

PMID:
19250787
15.

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.

Svenson M, Geborek P, Saxne T, Bendtzen K.

Rheumatology (Oxford). 2007 Dec;46(12):1828-34.

PMID:
18032541
16.

Commentary: antibodies reacting with the infliximab Fab portion--something new? Authors' reply.

Nielsen CH, Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B.

Aliment Pharmacol Ther. 2013 Sep;38(5):552-3. doi: 10.1111/apt.12426. No abstract available.

17.

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.

N Engl J Med. 2003 Feb 13;348(7):601-8.

18.

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.

Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y.

Aliment Pharmacol Ther. 2012 Mar;35(6):714-22. doi: 10.1111/j.1365-2036.2012.04997.x. Epub 2012 Jan 30.

19.

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD.

Steenholdt C, Brynskov J, Bendtzen K.

Aliment Pharmacol Ther. 2012 Sep;36(5):499-500; author reply 501. doi: 10.1111/j.1365-2036.2012.05204.x. No abstract available.

20.

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.

Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A.

Gut. 2012 Feb;61(2):321; author reply 322. doi: 10.1136/gut.2010.236869. Epub 2011 Feb 17. No abstract available.

PMID:
21330576

Supplemental Content

Support Center